Anzeige
Mehr »
Donnerstag, 05.06.2025 - Börsentäglich über 12.000 News
Kupfer wird knapp! Jetzt mischen sich Medien ein - und ein Explorer liefert die Story zur Fantasie
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0ESMG | ISIN: FR0010259150 | Ticker-Symbol: I7G
Tradegate
05.06.25 | 11:49
104,40 Euro
-0,10 % -0,10
1-Jahres-Chart
IPSEN SA Chart 1 Jahr
5-Tage-Chart
IPSEN SA 5-Tage-Chart
RealtimeGeldBriefZeit
104,30104,5011:55
104,30104,5011:55

Aktuelle News zur IPSEN Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiDividendenbekanntmachungen (04.06.2025)4.777 Unternehmen  ISIN-Code  Dividende (Währung)  Dividende (EUR)  ADESSO SE  DE000A0Z23Q5 - 0,75 EUR  AGEAS SA/NV  BE0974264930 - 2 EUR  AIR LEASE CORPORATION  US00912X3026  0,22 USD  0,1934 EUR  ANALOG...
► Artikel lesen
MiDeutsche Bank resumes Ipsen stock with buy rating citing Somatuline5
IPSEN Aktie jetzt für 0€ handeln
MoIpsen Pharma: Ipsen S.A. - Initiation of the share buy-back program1
SaIpsen Pharma: Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde regimen in metastatic pancreatic adenocarcinoma464Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics...
► Artikel lesen
21.05.Ipsen Pharma: Ipsen S.A. - Annual General Meeting held on 21 May 2025305Annual General Meeting of Ipsen S.A. held on 21 May 2025 All the resolutions submitted to the shareholders' vote have been adopted PARIS, FRANCE, 21 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY)...
► Artikel lesen
20.05.GENFIT S.A.: GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen's Iqirvo in Italy164Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 20, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients...
► Artikel lesen
12.05.Ipsen Pharma: Ipsen - April 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital4
07.05.Ipsen Pharma: Late-breaking exploratory data highlights the impact of IQIRVO (elafibranor) on fatigue and provides mechanistic insights into anti-inflammatory and symptom-related effects in patients with primary biliary cholangitis471Additional late-breaking data suggests up to twice as many patients treated with IQIRVO® achieved a clinically meaningful improvement in fatigue compared to placebo after 52 weeks of treatmentIQIRVO...
► Artikel lesen
06.05.Ipsen Appoints EVP, Strategy & Transformation5
06.05.Ipsen Pharma: Ipsen appoints Laura Réveillon as EVP, Strategy & Transformation388PARIS, FRANCE, 06 May 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven biopharmaceutical company, announced today the appointment of Laura Réveillon, PhD as EVP, Strategy & Transformation...
► Artikel lesen
30.04.Ipsen Pharma: Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2025 Annual General Meeting1
28.04.GENFIT S.A.: Positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025204Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients...
► Artikel lesen
25.04.Ipsen's elafibranor shows promise in rare liver disease primary sclerosing cholangitis2
24.04.Ipsen Pharma: Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication383Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment optionsPatients...
► Artikel lesen
17.04.Ipsen's liver disease drug Iqirvo off to promising launch in battle with Gilead's Livdelzi8
16.04.Ipsen S.A. reports Q1 results2
16.04.Ipsen posts 11.7% Q1 sales growth, maintains 2025 guidance amid pipeline progress3
16.04.Ipsen Pharma: Ipsen delivers strong sales in the first quarter 2025 and confirms its full-year guidance1.007Total sales growth of 11.6% at CER1, or 11.7% as reported, driven by all three therapeutic areas and including an increasing contribution from Iqirvo and Bylvay.Tovorafenib regulatory submission...
► Artikel lesen
14.04.Ipsen Pharma: Ipsen - March 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital1
08.04.Ipsen Pharma: Ipsen publishes its 2024 Universal Registration Document1
Seite:  Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1